Publications by authors named "L Nattkemper"
Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization whose mission is to improve the availability of evidence-based, consensus-driven outcome measures for dermatological diseases. IDEOM facilitates collaboration between stakeholders from various backgrounds, including researchers, patients, physicians, and industry representatives, to develop objective benchmark metrics that enable better treatment and management of dermatologic conditions.
Summary: The 2023 IDEOM Annual Meeting was held June 23-24, 2023.
Article Synopsis
- B-type natriuretic peptide (BNP) is a neuropeptide associated with various types of itch, showing elevated levels in patients undergoing hemodialysis.
- A study evaluated BNP and N-terminal pro-BNP levels in patients with chronic itch and found a correlation between these levels and itch severity, particularly in those with chronic pruritus of unknown origin.
- Experiments in mice confirmed that increased BNP levels lead to significant scratching, supporting the idea that BNP could play a central role in itch signaling in the spinal cord.
Article Synopsis
- The study investigates the role of Caveolin-1 (Cav1), Caveolin-2 (Cav2), and Cavin-1 in psoriasis vulgaris and its subtypes by analyzing skin biopsy samples.
- Researchers found that Cav1 is generally downregulated across all types of psoriasis, with nail, plaque, and palmoplantar psoriasis showing the most significant reductions.
- The findings suggest that Cav1 may serve as a universal biomarker for psoriasis, while Cav2 and Cavin-1 show specific downregulation mainly in nail and pustular psoriasis, indicating potential targets for treatment.
Botulinum toxin type A (Botox) is thought to have antipruritic effects through inhibition of pruritic factors, including acetylcholine, substance P, and glutamate. The aim of this randomized, single-blind, placebo-controlled trial was to test the effect of botulinum toxin type A on cowhage, a non-histaminergic model for chronic itch. Botulinum toxin type A was injected into the arm of 35 healthy subjects, with a saline control injected into the contralateral arm.
View Article and Find Full Text PDF